Concurrently, IGF-1R targeting in combination with other existing therapeutic options, including cytotoxic agents, radiotherapy, and castration, ought to be attempted to look for a novel strategy for the treatment of prostate cancer. This evidence concerns the gene IGF1R and prostate carcinoma.